Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool June 25, 2008 Brian Orelli	An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool July 26, 2007 Brian Orelli	Barr Gets Sued, Again This is starting to be a bad habit at Barr Pharmaceutical. The drug maker has just been sued for the third time in as many weeks. The latest one is by Schering-Plough, over patent infringement of its brain cancer treatment drug.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool August 9, 2007 Brian Orelli	Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool June 27, 2008 Brian Orelli	Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool April 10, 2007 Brian Lawler	Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
The Motley Fool August 8, 2008 Rich Duprey	Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.
The Motley Fool April 1, 2008 Brian Lawler	The Endo a Patent? Endo sues to protect a lead drug from generic competition.
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool July 30, 2007 Brian Orelli	Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool September 19, 2006 Brian Lawler	Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 28, 2007 Brian Lawler	Worrisome Watson The maker of generic drugs could have a challenging year ahead. Investors, take note.
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
Chemistry World June 14, 2013 Phillip Broadwith	Pfizer and Takeda win $2.15bn in patent payout Pfizer and Takeda will share a $2.15 billion settlement after suing generic drugmakers Teva and Sun Pharmaceuticals for patent infringement.
The Motley Fool August 3, 2007 Brian Orelli	Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool February 28, 2007 Brian Lawler	Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note.
The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool April 27, 2011 Frank Vinluan	Inspire's Pink Eye Drug AzaSite Draws Generic Challenge This sought-after drug could soon be facing generic competition.
The Motley Fool March 29, 2011 Brian Orelli	Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool December 3, 2008 Brian Orelli	High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool November 10, 2006 Brian Lawler	Watson Doesn't Wow Investors The generic drug developer made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter. Investors, take note.
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
The Motley Fool May 22, 2008 Brian Orelli	Wyeth's Never-Ending Generic Woes Novartis jumps on the generic Protonix bandwagon.
The Motley Fool June 30, 2006 Stephen D. Simpson	Barr Labs and Pliva: Round 2 The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs win this battle yet. Investors, take note.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.